Search results

Showing 1 – 9 of 9 results.
Curated

Better Rehabilitation Through Better Characterization of Treatments: Development of the Manual for Rehabilitation Treatment Specification [Methods Study], United States, 2014-2018 (ICPSR 39571)

Released/updated on: 2025-11-24
Geographic coverage: United States
Time period: 2014-01-01--2018-01-01

Many people have health problems that affect how well they can do normal activities, either for a short time or for their lifetime. These problems may be present from birth or result from illness, injury, or aging. Rehabilitation, or rehab, can help patients regain the ability to do normal activities. Rehab providers include doctors, nurses, psychologists, and physical, occupational, speech, or language therapists.

Rehab treatments often lack a common definition. Rehab providers often name treatments by the type of professional who delivers them or the problem they treat, rather than by the content of the treatment. Also, treatments can vary across rehab providers. Using a standard way to define rehab treatments may help researchers compare these treatments.

In this study, the research team created and tested a manual to help rehab providers use standard ways to define rehab treatments.

Curated

Causal Analyses of Electronic Health Record Data for Assessing the Comparative Effectiveness of Treatment Regimens [Methods Study], United States, 2014-2019 (ICPSR 39581)

Released/updated on: 2025-11-11
Geographic coverage: United States
Time period: 2014-01-01--2019-01-01

Patients with chronic health problems, such as diabetes, often need to change treatment plans over time to improve their health. To help with this process, doctors can monitor patients' health through follow-up clinic visits and lab tests. Doctors may also suggest changing a treatment plan in response to visits or lab test results. When a treatment plan changes in this way, it's called a dynamic treatment plan. In this study, the research team developed and tested new statistical methods to learn how dynamic treatment plans and choices about follow-up care affect patients' health. These methods use electronic health records, or EHRs. Using EHRs is helpful because they have data on

  • What treatments patients have received over time
  • How treatments have affected patients' health
  • Follow-up information such as lab test results

But the data may differ for patients based on when and why they go to the doctor. These differences make it hard for researchers to accurately know the effect of dynamic treatment plans across many patients.

To access the methods and software, please visit the simcasual R Package.

Curated

Causal Inference for Effectiveness Research in Using Secondary Data [Methods Study], 2013-2018 (ICPSR 39521)

Released/updated on: 2025-10-14
Time period: 2013-01-01--2018-01-01

Comparative effectiveness research compares two or more treatments to see which one works better for which patients. Electronic healthcare data are useful for this type of research. These data come from medical records and insurance claims. The data include information about how well patients respond to treatments. But many things--not just treatments--affect whether a patient's health improves.

How well a patient responds to a treatment may depend on the patient's age or what medicines the patient takes. It could also depend on what other health problems a patient has and how severe those problems are. Or a doctor may suggest one treatment instead of another because of a patient's personal situation and health. Researchers need ways to determine whether changes in a patient's health result from a certain treatment or something else.

Different statistical methods help researchers account for the various things that can affect treatment results. But researchers don't know which methods work best. This study compared several methods. The team looked at how well the methods worked to predict patients' responses to treatment, taking into account their personal situations and health. The team then created a computer program to help researchers use the methods.

To access the methods and software, please visit the Hdps GitHub and TargetedLearning GitHub.

Curated

Comparing Two Ways to Manage Symptoms for Patients Who Have Chronic Migraine and Frequent Medication Use (The MOTS Trial), United States, 2017-2020 (ICPSR 38546)

Released/updated on: 2022-12-14
Geographic coverage: United States
Time period: 2017-02-20--2020-12-22
The Medication Overuse Treatment Strategy (MOTS) research trial sought to understand the relationship between individuals who suffer from chronic migraines and their use (or overuse) of medications to treat their migraines. A diagnosis of chronic migraines means that a person experiences headaches on 15 days or more per month with at least 8 of those days meeting the diagnostic criteria for migraine with or without aura. Of the nearly 7 million individuals in the United States who suffer from chronic migraines more than half of them overuse medication intended to relieve the symptoms. However, that overuse can bring about other medical issues. This research trial enrolled 720 chronic migraine sufferers from 34 clinics across the country. The subjects were randomized into two groups. A total of 361 patients were randomized to the treatment strategy that included migraine-preventive therapy with switching off the overused medication to an alternative used with a limited frequency, while 359 patients were randomized to migraine-preventive medication with continuation of the overused medication with no maximum limit.
Curated

Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA), United States, 2016-2020 (ICPSR 38541)

Released/updated on: 2022-11-14
Geographic coverage: United States
Time period: 2016-05-03--2021-06-21

Antibiotics are considered a feasible treatment for appendicitis, yet appendectomy remains the treatment standard in the United States. Previous randomized trials comparing these treatments excluded important subgroups and recruited small sample sizes but questions remain about the applicability of these previous findings. This study conducted the Comparison of Outcomes of antibiotic Drugs and Appendectomy (CODA) randomized clinical trial to compare antibiotics with appendectomy among adults with appendicitis, including those with appendicolith. Those recruited comprised a diverse population, compared an overall measure of health status as the primary outcome, and included several secondary clinical and patient-reported outcomes, complications, and measures of healthcare utilization.

Curated

Comprehensive Post-Acute Stroke Services (COMPASS) Study, North Carolina, 2016-2018 (ICPSR 38185)

Released/updated on: 2021-10-07
Geographic coverage: North Carolina, United States
Time period: 2016-07-01--2018-03-31

The Comprehensive Post-Acute Stroke Services (COMPASS) Study is a pragmatic cluster-randomized clinical trial that evaluated the real-world effectiveness of the COMPASS transitional care (COMPASS-TC) model compared to usual care among adult stroke and transient ischemic attack (TIA) patients discharged home between 2016 and 2018. In Phase 1, 40 North Carolina hospital units were randomized 1:1 to the COMPASS-TC intervention or usual care, stratified by stroke patient volume and stroke center certification. In Phase 2, hospitals randomized to usual care crossed over to implement COMPASS-TC, and hospitals randomized to the intervention sustained COMPASS-TC. The intervention was patient-centered and assessed social and functional determinates of health to inform individualized care plans for secondary prevention, recovery, and referrals to services and community-based resources. COMPASS-TC was consistent with Centers for Medicare and Medicaid Services (CMS) TC management reimbursement requirements.

The primary outcome was functional status (Stroke Impact Scale-16; SIS-16) at 90 days; secondary outcomes were mortality, disability, medication adherence, depression, cognition, self-rated health, fatigue, care satisfaction, home blood pressure monitoring, falls, and caregiver strain. Telephone interviewers, blinded to treatment assignment, assessed these outcomes at 90 days.

Curated

Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS), United States, 2017-2020 (ICPSR 39186)

Released/updated on: 2025-07-01
Geographic coverage: United States
Time period: 2017-01-01--2020-01-01
This study was a multicenter, randomized, controlled, rater-blinded, phase 4, non-inferiority trial. Individuals with multiple sclerosis of any subtype, 55 years or older, with no relapse within the past 5 years or new MRI lesion in the past 3 years while continuously taking an approved disease-modifying therapy were enrolled at 19 multiple sclerosis centers in the USA. Participants were randomly assigned (1:1 by site) with an interactive response technology system to either continue or discontinue disease-modifying therapy. Relapse assessors and MRI readers were masked to patient assignment; patients and treating investigators were not masked. The primary outcome was percentage of individuals with a new disease event, defined as a multiple sclerosis relapse or a new or expanding T2 brain MRI lesion, over 2 years. The study assessed whether discontinuation of disease-modifying therapy was non-inferior to continuation using a non-inferiority, intention-to-treat analysis of all randomly assigned patients, with a predefined non-inferiority margin of 8%.
Curated

Improving Trial Design and Analysis for Treatments for Rare Diseases [Methods Study], 2020 (ICPSR 39118)

Released/updated on: 2024-06-10

A rare disease is one that affects fewer than 200,000 people in the United States. Because few people have these diseases, clinical studies on treatments can be hard to conduct. One way to study rare disease treatments is with an small n sequential multiple assignment randomized trial (snSMART) study.

snSMART studies have two stages. In the first stage, researchers assign patients to a treatment by chance. In the second stage, patients may stay with the same treatment or switch treatments. Patients stay on the same treatment if it's working well. If the treatment isn't working, researchers assign patients by chance to a new treatment.

snSMARTs can help researchers learn more from a smaller number of patients than a standard clinical study. But most current methods for analyzing snSMARTs use data only from the first stage, which can lead to inefficient results.

In this project, the research team developed and tested new methods that use data from both stages to analyze snSMARTs. The team compared results from the new methods to actual treatment effectiveness to see:

  • Bias, or whether results are too high or too low
  • Efficiency, or how big the difference is between the results and actual treatment effectiveness

This study contains two supplementary documentation files. There is no data included in this release.

Curated

Methods for Heterogeneity of Treatment Effects: Random Forest Counterfactual Machines [Methods Study], Cleveland, Ohio, 2014-2019 (ICPSR 39559)

Released/updated on: 2025-11-24
Geographic coverage: United States, Ohio, Cleveland
Time period: 2014-01-01--2019-01-01

Patients may respond differently to the same treatment due to individual traits such as age or gender. Knowing how different traits can affect a patient's response to treatment can help doctors and patients make better treatment decisions. For example, this information can help doctors know what types of cancer medicines work better for certain patients. This project focuses on improving the methods that researchers use to compare how treatments work for different patients.

In this project, the research team developed and tested a statistical method called random forests, or RF. RF is a way to analyze data using a technique called machine learning. In machine learning, computers use data to learn how to perform different tasks with little or no human input. Many types of RF methods exist. The team compared multiple RF methods to learn how well the methods would work to find out how patients with different traits respond to the same treatment.

To access the R package, please visit the randomForestSRC CRAN webpage.